Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this World View article, eminent immunologist Peter Doherty suggests that we should consider the COVID-19 crisis as a training run for future, potentially worse pandemics and organize accordingly.
This preprint further characterizes a superantigen motif identified in SARS-CoV-2 spike protein and evaluates a monoclonal antibody targeting this region that can neutralize live virus.
Two studies from the Oxford COVID-19 vaccine team describe the immune responses that develop in healthy adults following a single dose or two doses of their adenovirus vector-based COVID-19 vaccine.
Wieland et al. report that the tumour microenvironment of human papillomavirus (HPV)-positive head and neck squamous cell carcinomas contains HPV-specific B cells that actively secrete HPV-specific antibodies.
In February 2021, Nature Reviews Immunology launches the first of its monthly ‘Preprint Watch’ columns. Here, we explain the rationale for our coverage of preprints and the precautions we have taken to guard against their improper use.
A recent study in Science Immunology describes a new approach to selectively eliminate pathogenic CD4+ T cells in inflammatory bowel disease by activating them in the presence of metabolic checkpoint inhibition.
Here, Veldhoen and Simas discuss why immunity to SARS-CoV-2 in populations may ultimately be driven by the endemic presence of the virus and not rely on continued mass vaccination programmes.